Recruiting
Phase 2

Ravulizumab

Sponsor:

Mayo Clinic

Code:

NCT06333652

Conditions

Preeclampsia

Eligibility Criteria

Sex: Female

Age: 18 - 50

Healthy Volunteers: Not accepted

Interventions

Ravulizumab

Study Details

Brief summary:

The researchers are testing a medication named ravulizumab for the treatment of severe preeclampsia and Hemolysis, Elevated Liver enzymes, Low Platelets (HELLP) syndrome.

Conditions

Preeclampsia

Study ID

NCT06333652

Start date

Apr 1, 2027

Status verified date

Oct, 2026

Completion date

Dec 31, 2028

Anticipated

Primary completion date

Dec 31, 2028

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: Female

Age: 18 - 50

Healthy Volunteers: Not accepted

Inclusion Criteria:

  • Individuals with < 34 0/7 weeks of gestation.
  • Individuals with severe preeclampsia or HELLP features.

Exclusion Criteria:

  • Pregnant female patients presenting with disseminated intravascular coagulopathy (DIC).
  • Individuals with non-reassuring fetal status requiring delivery, non-viable fetuses, previable pregnancy (<23 0/7 weeks gestation), stroke, in utero fetal demise, known atypical hemolytic uremic syndrome, familial or acquired thrombocytopenia purpura, paroxysmal nocturnal hemoglobinuria, allergy to Ravulizumab, inability or unwillingness to sign informed consent.

Study Design

Enrollment

14 participants

Anticipated

Intervention Model

Single group

Primary purpose

Treatment

Interventions and Outcome Measures

Arms

experimental: Revulizumab Treatment

Subjects will receive an single-dose infusion of Ravulizumab.

Interventions

Ravulizumab

Intravenous infusion 100 mg/ml

Primary outcome measure

  • Alternative Complement Pathway Biomarkers at time of delivery [ Time Frame: Baseline ]

Central Contacts and Locations

Central contacts

Gonzalez Suarez

507-284-2511

Locations

Mayo Clinic Minnesota

Recruiting

Rochester, Minnesota, United States, 55905

Contacts

Maria L. Gonzalez Suarez, MD,PhD

5072844083gonzalezsuarez.maria@mayo.edu

More Information

Sponsor

Mayo Clinic

Last update posted

Oct 22, 2026

Last verified

Oct, 2026

Keywords

  • Hemolysis
  • Elevated Liver enzymes
  • Low Platelets

Trial information was received from ClinicalTrials.gov and was last updated on 2026-10-25. This information was provided to ClinicalTrials.gov by Mayo Clinic on 2026-10-22. Recruitment status is synced daily from ClinicalTrials.gov and may not reflect the sponsor's current status. Confirm during your call.